Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Candonilimab Combined With All-trans Retinoic Acid for Prevention of Oral Cancer Recurrence in Patients With High-risk Oral Precancerous Lesions.

NCT06728631 is registered in ClinicalTrials.gov with Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University as lead sponsor.

NCT NCT06728631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06728631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Candonilimab Combined With All-trans Retinoic Acid for Prevention of Oral Cancer Recurrence in Patients With High-risk Oral Precancerous Lesions.
Lead sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2020
Completion date
December 31, 2026
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral cavity cancer, premalignant lesion